Invesco Dynamic Biotechnology & Genome ETF (PBE) Shares Sold by SignalPoint Asset Management LLC

Share on StockTwits

SignalPoint Asset Management LLC decreased its holdings in Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE) by 13.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,572 shares of the company’s stock after selling 1,183 shares during the quarter. SignalPoint Asset Management LLC owned approximately 0.15% of Invesco Dynamic Biotechnology & Genome ETF worth $450,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. CWM LLC raised its position in shares of Invesco Dynamic Biotechnology & Genome ETF by 663.5% during the third quarter. CWM LLC now owns 3,199 shares of the company’s stock worth $190,000 after acquiring an additional 2,780 shares during the last quarter. UBS Group AG raised its position in shares of Invesco Dynamic Biotechnology & Genome ETF by 3.4% during the first quarter. UBS Group AG now owns 99,466 shares of the company’s stock worth $4,896,000 after acquiring an additional 3,275 shares during the last quarter. First Capital Advisors Group LLC. bought a new stake in shares of Invesco Dynamic Biotechnology & Genome ETF during the third quarter worth $207,000. Trillium Asset Management LLC bought a new stake in shares of Invesco Dynamic Biotechnology & Genome ETF during the second quarter worth $215,000. Finally, Wagner Bowman Management Corp bought a new stake in shares of Invesco Dynamic Biotechnology & Genome ETF during the second quarter worth $216,000.

NYSEARCA PBE traded up $0.51 on Wednesday, reaching $50.71. The company had a trading volume of 1,360 shares, compared to its average volume of 21,578. Invesco Dynamic Biotechnology & Genome ETF has a 52 week low of $43.08 and a 52 week high of $60.49.

Invesco Dynamic Biotechnology & Genome ETF Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.

See Also: Fundamental Analysis – How It Helps Investors

Institutional Ownership by Quarter for Invesco Dynamic Biotechnology & Genome ETF (NYSEARCA:PBE)

Receive News & Ratings for Invesco Dynamic Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Dynamic Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply